Johnson & Johnson Submits Application to U.S. FDA Seeking Approval of Tremfya® (Guselkumab) for the Treatment of Moderately to Severely Active Crohn's Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.